Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 4, 2009, Pages 279-285

  Rubino, C M ^a,c   Bhavnani, S M ^a,c   Ambrose, P G ^a,c   Forrest, A ^a,c   Loutit, J S ^b  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b InterMune Inc   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antacids; Exposure response; Food; Idiopathic pulmonary fibrosis; IPF; Pharmacokinetics; Pirfenidone; PK; Safety

Indexed keywords

4' HYDROXYPIRFENIDONE; 5 CARBOXYPIRFENIDONE; 5 HYDROXYMETHYLPIRFENIDONE; ANTACID AGENT; DRUG METABOLITE; MYLANTA; PIRFENIDONE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY;

AGED; ANTACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOTRANSFORMATION; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; LINEAR MODELS; MALE; MIDDLE AGED; PYRIDONES; THERAPEUTIC EQUIVALENCY;

EID: 67349131293     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.03.003     Document Type: Article

References (18)

1. Lynch J, Toews G. Idiopathic pulmonary fibrosis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM, editors. Pulmonary diseases and disorders, 3 ed. New york: McGraw-Hill; 1998. p. 1069-1084.
2. Raghu G., Weycker D., Edelsberg J., Bradford W.Z., and Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174 (2006) 810-816
3. Khalil N., and O'Connor R. Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ 171 (2004) 153-160
4. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161 (2000) 646-664
5. Hewitson T.D., Kelynack K.J., Tait M.G., Martic M., Jones C.L., Margolin S.B., et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 14 (2001) 453-460
6. Iyer S.N., Margolin S.B., Hyde D.M., and Giri S.N. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 24 (1998) 119-132
7. Kehrer J.P., and Margolin S.B. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett 90 (1997) 125-132
8. Azuma A., Nukiwa T., Tsuboi E., Suga M., Abe S., Nakata K., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040-1047
9. Raghu G., Johnson W.C., Lockhart D., and Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 159 (1999) 1061-1069
10. Nagai S., Hamada K., Shigematsu M., Taniyama M., Yamauchi S., Izumi T., et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 41 (2002) 1118-1123
11. D'Argenio D.Z., and Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9 (1979) 115-134
12. D'Argenio DZ, Schumitzky A. ADAPT user's guide: pharmacokinetic/pharmacodynamic systems analysis software; 2003.
13. Jusko WJ. Guidelines for the collection and analysis of pharmacokinetic data; 1992. p. 1-43.
14. Akaike H. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66 (1979) 237-242
15. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15 (1987) 657-680
16. FDA Guidance for Industry. Food-effect bioavailability and fed bioequivalence studies; December 2002.
17. FDA Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations; March 2003.
18. Giri S.N., Wang Q., Xie Y., Lango J., Morin D., Margolin S.B., et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 23 (2002) 203-211